<DOC>
	<DOCNO>NCT01974206</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ASP0113 compare placebo reduce incidence cytomegalovirus ( CMV ) viremia CMV-seronegative subject receive kidney CMV-seropositive donor . This study also evaluate safety ASP0113 patient population .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Vaccine , ASP0113 , Cytomegalovirus ( CMV ) -Seronegative Kidney Transplant Recipients Receiving Organ From CMV-Seropositive Donor</brief_title>
	<detailed_description>Subjects follow one year first study drug injection . This primary study period . Subjects follow 4.5 year completion primary study ass long-term safety vaccine .</detailed_description>
	<criteria>CMV negative subject receive CMV seropositive kidney ( live decease ) Subject start valganciclovir ganciclovir within 10 day transplant receive Randomization . Subject plan undergo course CMVspecific prophylactic therapy antiviral drug duration great 100 day . Subject receive one month prior transplant plan receive CMV immunoglobulin . Subject CMV viremia CMV disease time transplant time Randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ASP0113</keyword>
	<keyword>Cytomegalovirus ( CMV )</keyword>
	<keyword>Kidney Transplantation</keyword>
</DOC>